Contact Us

Phone
Alison Hey-Cunningham +61 2 9515 6651    

Email
alison.hey-cunningham@sydney.edu.au

Address
Centre of Research Excellence in Pulmonary Fibrosis
Respiratory Medicine and Sleep Unit
Level 11, Royal Prince Alfred Hospital
Camperdown NSW 2050

Facebook

Twitter

Online Enquiry

* Required fields

Publications

2021

Teoh, AKYCorte, TJContemporary Concise Review 2020: Interstitial lung diseaseRespirology202126604– 611https://doi.org/10.1111/resp.14063

Liu G, Corte T, Philp AM, Travis MA, Schilter H, Hansbro NG, Burns CJ, Eapen MS, Sohal SS, Burgess JK, Hansbro PM. Therapeutic targets in lung tissue remodelling and fibrosis. Pharmacology and Therapeutics. accepted 5.3.21.

Nambiar S, Clynick B , How BS, King A, Walters EH, Goh NS, Corte TJ, Trengove R, Tan D and  Moodley Y  (2021). There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)Respiratory Research22(1), [105]. https://doi.org/10.1186/s12931-021-01682-3

Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database of Systematic Reviews. 2021(2).

Khor YH, Dudley KA, Herman D, Jacobs SS, Lederer DJ, Krishnan JA, Holland AE, Ruminjo JK, Thomson CC. Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung Disease. Annals of the American Thoracic Society. 2021 (In press).

Khor YH, Harrison A, Robinson J, Goh NSL, Glaspole I, McDonald CF. Moderate resting hypoxaemia in fibrotic interstitial lung disease. European Respiratory Journal. 2021;57(1):2001563.

Cox IA, de Graaff B, Corte TJ, Glaspole, I, Chambers DC, Moodley Y, Teoh A, Walters EH, Palmer AJ. Trends in nintedanib and pirfenidone utilisation for Idiopathic Pulmonary Fibrosis in Australia. Australian Health Review (accepted for publication, February, 2021)

Jee AS, Parker M, Bleasel J, Troy L, Jo HE, Lau E, Teoh AKY Adelstein SA, Webster S, Corte TJ, Baseline characteristics and survival of an Australian interstitial pneumonia with autoimmune features (IPAF) cohort. Respiration (accepted not yet published)

Mackintosh JA, Glenn L, Barnes H, Dunn E, Bancroft S, Reddy T, Teoh AKY, Troy L, Jo H, Geis M, Glaspole I, Grainge C, Corte T, Chambers DC, Hopkins P. The benefits of a virtual interstitial lung disease multi-disciplinary meeting in the face of COVID-19. Respirology April 2021 https://doi.org/10.1111/resp.14062

Philip J, Collins A, Smallwood N, Chang YK, Mo L, Yang IA, Corte T, McDonald CF, Hui D. Referral criteria to palliative care for patients with respiratory disease: a systematic review. European Respiratory Journal 2021. doi: 10.1183/13993003.04307-2020

Proudman SM, Corte TJ. Are serum biomarkers useful in the management of systemic sclerosis-associated interstitial lung disease? Respirology. 2021 Feb 20. doi: 10.1111/resp.14017. Online ahead of print.

Kanjrawi AA, Mathers L, Webster S, Corte TJ, Carey S. Nutritional status and quality of life in interstitial lung disease: a prospective cohort study. BMC Pulmonary Medicine. 2021 Feb 5;21(1):51. doi: 10.1186/s12890-021-01418-5.

Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, Jouneau S, Michael A, Quaresma M, Rohr KB, Russell AM, Stowasser S, Maher TM; INMARK trial investigators. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal Jan 8. doi: 10.1183/13993003.01518-2020

Wageck B, Cox NS, Lee J, Romero L, Holland AE. Characteristics of pulmonary rehabilitation programs following an exacerbation of chronic obstructive pulmonary disease: a systematic review. Journal of Cardiopulmonary Rehabilitation and Prevention. 2021;41(2):78-87.

2020

Xu J, Xu X, Jiang L, Dua Kamal, Hansbro PM, Liu G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respiratory Research. 2020; 21(1): 182.

Mehta M, Satija S, Paudel KR, Liu G, Chellappan DK, Hansbro PM, Dua K. Incipient need of targeting airway remodelling using advanced drug delivery in chronic respiratory diseases, Future Medicinal Chemistry. 12(10):873-875.

Ali MK, Kim RY, Brown AC, Donovan C, Vanka KS, Mayall JR, Liu G, Pillar AL, Freeman BJ, Xenaki D, Borghuis T, Karim R, Pinkerton JW, Aryal R. Heidri M, Martin KL, Burgess JK, Oliver BG, Trinder D, Johnstone DM, Milward EA, Hansbro PM Horvat JC. Critical role for iron accumulation in the pathogenesis of fibrotic lung disease. Journal of Pathology. 251(1): 49-62. [IF:5.979].

Khor YH, Ryerson CJ, Landry SA, Howard ME, Churchward TJ, Edwards BA, Hamilton GS, Joosten SA. Interstitial lung disease and obstructive sleep apnoea. Sleep Medicine Reviews. 2020.

Holland AE, Dowman L, Smallwood N. Patient-reported Outcomes for Clinical Trials in Idiopathic Pulmonary Fibrosis: New Opportunities to Understand How Patients Feel and Function. American Journal of Respiratory and Critical Care Medicine. 2020 Dec 15;202(12):1620-1622doi: 10.1164/rccm.202007-2775ED. 

Holland AE, Corte T, Chambers DC, Palmer AJ, Ekström MP, Glaspole I, Goh NSL, Hepworth G, Khor YH, Hoffman M, Vlahos R, Sköld M, Dowman L, Troy LK, Prasad JD, Walsh J, McDonald CF. Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial. BMJ Open. 2020 Dec 13;10(12):e040798. doi: 10.1136/bmjopen-2020-040798

Holland AE, Malaguti C, Hoffman M, Lahham A, Burge AT, Dowman L, May AK, Bondarenko J, Graco M, Tikellis G, Lee JY, Cox NS. Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: A rapid review. Chronic Respiratory Disease 2020 Jan-Decdoi: 10.1177/1479973120952418. 

Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: A systematic review. European Respiratory Review. 2020;29(157):190158.

Khor YH, Holland AE, Goh NSL, Miller BR, Vlahos R, Bozinovski S, Lahham A, Glaspole I, McDonald CF. Ambulatory oxygen in fibrotic interstitial lung disease: a pilot, randomised, triple-blinded, sham-controlled trial. Chest. 2020;181(1):234-244.

Sweeney DJ, Khor YH*, Goh NSL* (* joint senior authors). The Unmet Care Needs of Progressive Fibrosing Interstitial Lung Disease. Respirology. 2020;25(12):1231-1232.

Cooper WA, Mahar A, Myers JL, Grainge C, Corte TJ, Williamson JP, Vallely MP, Lai S, Mulyadi E, Torzillo PJ, Phillips MJ, Lau EMT, Raghu G, Troy LK. Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features: Further Lessons from COLDICE, a Prospective Multi-Center Study. American Journal of Respiratory and Critical Care Medicine. 2020 Dec 7. doi: 10.1164/rccm.202009-3688OC. 

Tikellis G, Tong A, Lee JYT, Corte TJ, Hey-Cunningham AJ, Bartlett M, Crawford T, Glaspole I, Price J, Maloney J, Holland AE. Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers. Thorax. 2020  doi: 10.1136/thoraxjnl-2020-215731. 

Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, Keir GJ. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 2021 Jan;26(1):23-51. doi: 10.1111/resp.13977. 

Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European Respiratory Review. 2020 Nov 5;29(158):200154. doi: 10.1183/16000617.0154-2020. 

Moore I, Wrobel J, Rhodes J, Lin Q, Webster S, Jo H, Troy L, Grainge C, Glaspole I, Corte TJ; Australasian ILD Registry. Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. BMC Pulmonary Medicine. 2020 Oct 2;20(1):257. doi: 10.1186/s12890-020-01297-2.

McLean AEB, Webster SE, Fry M, Lau EM, Corte P, Torzillo PJ, Troy LK, Jo HE, Geis M, Rhodes JE, Cleary S, Spencer L, Corte TJ. Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinic. Respirology. 2021 Jan;26(1):80-86. doi: 10.1111/resp.13913. 

Parker MJS, Corte TJ. First risk, next reward? A new clinico-radiological risk model predicts mortality in rheumatoid arthritis-associated interstitial lung disease. Respirology. 2020 (12):1225-1226. doi: 10.1111/resp.13924.

Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, Inoue Y, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2020 Aug 1;202(3):e36-e69. doi: 10.1164/rccm.202005-2032ST.

Abramson MJ, Murambadoro T, Alif SM, Benke GP, Dharmage SC, Glaspole I, Hopkins P, Hoy RF, Klebe S, Moodley Y, Rawson S, Reynolds PN, Wolfe R, Corte TJ, Walters EH; Australian IPF Registry. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study. Thorax. 2020 (10):864-869. doi: 10.1136/thoraxjnl-2019-214478. 

Lau EMT, Grainge C, Williamson JP, Corte TJ, Cooper WA, Phillips MJ, Torzillo PJ, Vallely MP, Raghu G, Troy LK. Methodologies of COLDICE and Cryo-PID studies: details make the difference. Annals of Translational Medicine. 2020 Jun;8(12):781. doi: 10.21037/atm-20-3769.

Clynick B, Jo HE, Corte TJ, Glaspole IN, Grainge C, Hopkins PMA, Reynolds PN, Chapman S, Walters EH, Zappala C, Keir GJ, Cooper WA, Mahar AM, Ellis S, Goh NS, Baltic S, Ryan M, Tan DBA, Moodley YP. Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis. European Respiratory Journal 2020, Sep 10;56(3):1902058. doi: 10.1183/13993003.02058-2019. 

Teoh AKY, Corte TJ. Nonspecific Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine. 2020 Apr;41(2):184-201. doi: 10.1055/s-0040-1708499. 

Holland A, Smallwood N, Dowman L Patient-reported outcomes for clinical trials in idiopathic pulmonary fibrosis: new opportunities to understand how patients feel and function. American Journal of Respiratory and Critical Care Medicine August 2020. doi: 10.1164/rccm.202007-2775ED

Glenn LM, Corte TJ. Diagnosing idiopathic pulmonary fibrosis: Has the time for surgical lung biopsy passed? Respirology 2020. doi: 10.1111/resp.13909. 

Teoh AKY, Jo HE, Chambers DC, Symons K, Walters EH et al. Blood monocyte counts as a potential prognostic marker for IPF: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal 2020, 55:1901855. doi: 10.1183/13993003.01855-2019.

Khor YH, Holland AE, Goh NSL et al. Ambulatory oxygen in fibrotic interstitial lung disease: A pilot, randomised, triple-blinded, sham-controlled trial. Chest 2020, 158 (1): 234-244. doi: 10.1016/j.chest.2020.01.049.

Tikellis G, Lee JYT, Corte TJ, Maloney J et al. Peer Connect Service for people with PF in Australia: Participants' experiences and process evaluation. Respirology 2020. doi: 10.1111/resp.13807.

Lee JYT, Tikellis, G, Corte TJ et al. The supportive care needs of people living with pulmonary fibrosis and their caregivers: A systematic review.European Respiratory Review 20, 29:

Teoh AKY, Glaspole I, Macansh S, Corte TJ. Importance of occupational exposure data: A national idiopathic pulmonary fibrosis registry perspective. American Journal of Respiratory and Critical Care Medicine 2020 May 1;201(9):1165-1167. doi: 10.1164/rccm.201911-2242LE.

Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA et al. Diagnostic accuracy of transbronchial lung cryobiopsy for Interstitial Lung Disease diagnosis (COLDICE): A prospective, comparative study. The Lancet Respiratory Medicine 2020, 8(2):171-181. doi: 10.1016/S2213-2600(19)30342-X.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T et al. Acute exacerbation of Idiopathic Pulmonary Fibrosis: International survey and call for harmonisation. European Respiratory Journal 2020, 55(4). doi: 10.1183/13993003.01760-2019.

Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; CHP Exposure Assessment Collaborators. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest. 2020 Jun;157(6):1506-1512. doi: 10.1016/j.chest.2019.12.018. 

Teoh AKY, Jo HE, Chambers DC, Symons K, Walters EH, Goh NS, Glaspole I, Cooper W, Reynolds P, Moodley Y, Corte TJ. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registryEuropean Respiratory Journal 2020 Apr 3;55(4):1901855. doi: 10.1183/13993003.01855-2019. 

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. 

Blokland, K. E. C., Pouwels, S. D., Schuliga, M., Knight, D. A., & Burgess, J. K. (2020). Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases. Clinical Science, 134(20), 2681-2706.

Schuliga, M., Read, J., Blokland, K. E., Waters, D. W., Burgess, J., Prêle, C., ... Knight, D. A. (2020). Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clinical Science, 134(7), 889-905.

Blokland, K. E. C., Waters, D. W., Schuliga, M., Read, J., Pouwels, S.D., Grainge, C. L., ... Knight, D. A.(2020). Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. Pharmaceutics, 12(4), [389].

Holland AE, Malaguti C, Hoffman M, et al. Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: A rapid review. Chronic Respiratory Disease. January 2020.

Cox I, de Graaff B, Ahmad H, Corte TJ, Walters HE, Palmer AJ. PRS18 The IMPACT of Idiopathic Pulmonary Fibrosis on Health State Utility Values: Evidence from Australia. Value in Health Regional Issues. 2020;22:S102.

2019

Liu G, Cooley MA, Jarnicki AG, Borhuis T, Nair PM, Tjin G, Hsu AC, Haw TJ, Fricker M, Harrison CL, Jones B, Hansbro NG, Wark PA, Horvat JC, Argraves WS, Oliver BG, Knight DA, Burgess JK, Hansbro PM. Fibulin-1c regulates transforming growth factor-b activation in pulmonary tissue fibrosis. JCI Insight, 2019. 4(16): e124529. 

Khor YH, Goh N, Miller B, Glaspole I, Holland AE, McDonald CF. A pilot randomised, controlled trial of ambulatory oxygen versus air via portable concentrator in fibrotic interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 2019, 199.

Khor YH, Goh NSL, Miller B, Glaspole I, Holland AE, McDonald CF. Exertional desaturation and prescription of ambulatory oxygen therapy in ILD. Respiratory Care 2019, 64(3):299-306. doi: 10.4187/respcare.06334.

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S et al. Implications of the diagnostic criteria of IPF in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology 2019, 24(4):361-368. doi: 10.1111/resp.13427. 

Culver DA, Behr J, Belperio JA, Corte TJ et al. Patient registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2019, 200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

Burnett K, Glaspole I, Holland AE. Understanding the patient's experience of care in Idiopathic Pulmonary Fibrosis. Respirology 2019, 24(3):270-277. doi: 10.1111/resp.13414.

Hoffman M, McDonald C, Corte T, Chambers D, Ekstrom M, Glaspole I, Goh N, Holland A. Effective delivery of ambulatory oxygen in interstitial lung disease - a crossover trial. European Respiratory Journal 2019, 54:2. doi: 10.1183/13993003.congress-2019.PA1226.

Holland AE, Lee J, Maloney J, Walsh J. Sharing experiences and offering mutual support: An evaluation of the Peer Connect Service for people with pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2019, 199:2.

Holland A, Lee J, Maloney J, Walsh J. Shared experiences, mutual support: Peer Connect Service for Pulmonary Fibrosis. Respirology 2019, 24:33.

Khor YH, Barnes H, NG Y, Goh N, McDonald CF, Holland AE. Prognosis of adults with idiopathic pulmonary fibrosis without effective therapies: A systematic review and meta-analysis. American Journal of Respiratory and Critical Care Medicine 2019, 199:2.

Clynick B, Jo H, Corte T, Glaspole I, Grainge C, Hopkins P et al. Differences in circulating nucleic acids between patients with stable and progressive lung function in Idiopathic Pulmonary Fibrosis. Respirology 2019, 24:35.

Clynick B, Jo H, Corte T, Glaspole I, Grainge C, Hopkins P et al. Circulating RNA differences between patients with stable and progressive lung function in Idiopathic Pulmonary Fibrosis. European Respiratory Journal 2019, 54(5):CP8. doi: 10.1183/13993003.02115-2018.

Glaspole I, Lancaster L, Hernandez P, Inoue Y et al. Nintedanib in patients with Idiopathic Pulmonary Fibrosis: Safety and tolerability. Respirology 2019, 24:34.

Hatch M, Goh N, Khor Y. Baseline inflammatory markers and survival in patients with Interstitial lung disease. Respirology 2019, 24:167.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4.

Jee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs. 2019 Sep;79(14):1511-1528. doi: 10.1007/s40265-019-01178-x.

Moodley YP, Corte TJ, Oliver BG, Glaspole IN, Livk A, Ito J, Peters K, Lipscombe R, Casey T, Tan DBA. Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis. Respirology. 2019 Nov;24(11):1111-1114. doi: 10.1111/resp.13668. 

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. 

Troy LK, Grainge C, Corte T, Williamson JP, Vallely MP, Cooper W, Mahar AM, Lai S, Mulyadi E, Torzillo PJ, Salamonsen M, Don G, Myers J, Raghu G, Lau EMT; COLDICE Investigator Team. Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research. 2019 Jun 21;6(1):e000443. doi: 10.1136/bmjresp-2019-000443.

Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, Corte TJ. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. European Respiratory Journal. 2019 Sep 30;54(3):1801797. doi: 10.1183/13993003.01797-2018.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, ...... Corte TJ, ....Wells AU et al.. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, Corte TJ. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons. Pharmacology and Therapeutics. 2019 Oct;202:40-52. doi: 10.1016/j.pharmthera.2019.05.014.

Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA; O2 Delphi Collaborators. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. European Respiratory Journal. 2019 Aug 8;54(2):1900421. doi: 10.1183/13993003.00421-2019. 

Jo HE, Corte TJ, Glaspole I, Grainge C, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Keir GJ, Cooper WA, Mahar AM, Ellis S, Macansh S, Goh NS. Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine. 2019 May 3;19(1):84. doi: 10.1186/s12890-019-0846-2.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, ....., Corte TJ, Glaspole I, ..... Prele C, et al. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ. Patient Registries in Idiopathic Pulmonary Fibrosis.American Journal of Respiratory and Critical Care Medicine. 2019 Jul 15;200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

Troy LK, Young IH, Lau EMT, Wong KKH, Yee BJ, Torzillo PJ, Corte TJ. Nocturnal hypoxaemia is associated with adverse outcomes in interstitial lung disease. Respirology. 2019 Oct;24(10):996-1004. doi: 10.1111/resp.13549. 

Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Research. 2019;5:00118-2019.

Burgess A, Goon K, Brannan JD, Attia J, Palazzi K, Oldmeadow C, Corte TJ, Glaspole I, Goh N, Keir G, Allan H, Chapman S, Cooper W, Ellis S, Hopkins P, Moodley Y, Reynolds P, Zappala C, Macansh S, Grainge C. Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology. 2019 Oct;24(10):988-995. doi: 10.1111/resp.13540. 

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Macansh S, Grainge C, Keir GJ, Hayen A, Henderson D, Klebe S, Heinze SB, Miller A, Rouse HC, Duhig E, Cooper WA, Mahar AM, Ellis S, McCormack SR, Ng B, Godbolt DB, Corte TJ. Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology. 2019 Apr;24(4):361-368. doi: 10.1111/resp.13427. 

Cullmann, K., Blokland, K. E. C., Sebe, A., Schenk, F., Ivics, Z., Heinz, N., & Modlich, U. (2019). Sustained and regulated gene expression by Tet-inducible "all-in-one" retroviral vectors containing the HNRPA2B1-CBX3 UCOE®. Biomaterials, 192, 486-499.

Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Wei, L., Schuliga, M., Jaffar, J., ... Knight, D. A. (2019). STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 61(1), 61-73.

McVey, M. J., Maishan, M., Blokland, K. E. C., Bartlett, N., & Kuebler, W. M. (2019). Extracellular vesicles in lung health, disease, and therapy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 316(6), L977-L989.

Hoffman M, Augusto VM, Eduardo DS, Silveira BMF, Lemos MD, Parreira VF. Inspiratory muscle training reduces dyspnea during activities of daily living and improves inspiratory muscle function and quality of life in patients with advanced lung disease. Physiotherapy Theory Practice. 2019 Aug 20:1-11

Khor YH, Glaspole I, Goh NSL. Therapeutic burden in interstitial lung disease: lessons to learn. Respirology. 2019;24(6):566-571. 

Nakazawa A, Dowman LM, Cox NS, McDonald CF, Hill CJ, Lee AL, Holland AE. Factors predicting progression of exercise training loads in people with interstitial lung disease. European Respiratory Journal Open Research. 2019 Oct;5(4). doi: 10.1183/23120541.00245-2018. 

2018

Glaspole I, Wells A, Behr J, Stansen W, Stowasser S, Maher T. Composite physiologic index in Idiopathic Pulmonary Fibrosis: Effects of nintedanib. Respirology 2018 23:125.

Barnes H, Goh N, Westall G, Holland A, Glaspole I. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Respirology 2018 23:124.

Abramson, MJ, Murumbadoro T, Alif SM, Benke G et al. Occupational and environmental risk factors for Idiopathic Pulmonary Fibrosis in Australia. European Respiratory Journal 2018 52. doi: 10.1183/13993003.congress-2018.PA5068.

Schuliga, M., Pechkovsky, D. V., Read, J., Waters, D. W., Blokland, K.E. C., Reid, A. T., ... Knight, D. A. (2018). Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts. Journal of Cellular and Molecular Medicine, 22(12), 5847-5861.

Waters DW, Blokland KEC, Pathinayake PS, Burgess JK, Mutsaers SE, Prele CM, Schuliga M, Grainge CL, Knight DA. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology 2018 Apr 26. doi: 10.1152/ajplung.00037.2018.

Jo HE and Corte TJ. Idiopathic Pulmonary Fibrosis. Australian Doctor 6 April 2018; 17-24. https://www.howtotreat.com.au/node/47341/1.

Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M. Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis. Scientific Reports (2018) 1, 3212. doi: 10.1038/s41598-018-20811-5.

Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nüssing S, Fox A, Chung AW, Laurie KL, Hurt AC, Rockman S, Lappas M, Loudovaris T, Mannering SI, Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. American Association for the Advancement of Science (2018) 10, 428. doi: 10.1126/scitranslmed.aan8405.

Pizzolla A, Nguyen TH, Sant S, Jaffar J, Loudovaris T, Mannering SI, Thomas PG, Westall GP, Kedzierska K, Wakim LM. Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. Journal of Clinical Investigations (2018) 128 (2):721-733.

Lavender M, Chia KS, Dwyer N, Corte TJ, Spencer L, Thakkar V, McWilliams T, Kotlyar E, Whitford H. Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. Expert Review of Respiratory Medicine. 2018 Nov;12(11):965-977. doi: 10.1080/17476348.2018.1527687.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V.  Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. 

Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P. Should Patients With Interstitial Lung Disease Be Seen by Experts? Chest. 2018 Sep;154(3):713-714. doi: 10.1016/j.chest.2018.05.044.

Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, Ryerson CJ. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018;96(4):314-322. doi: 10.1159/000489668. 

Kouranos V, Miranda G, Corte TJ, Renzoni EA. New treatment paradigms for connective tissue disease-associated interstitial lung disease. Current Opinion Pulmonary Medicine. 2018 Sep;24(5):453-460. doi: 10.1097/MCP.0000000000000508

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, Jones LJ, Hopkins P, Allan HM, Glaspole I, Corte TJ. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Medical Journal of Australia. 2018 Feb 5;208(2):82-88. doi: 10.5694/mja17.00799.

Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.

Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine 2018 Apr 15;197(8):1036-1044. doi: 10.1164/rccm.201710-1986OC.

Holland AE, Hill CJ, Dowman L, Glaspole I, Goh N, Lee AL, McDonald CF. Short and long term reliability of the 6-minute walk test in people with idiopathic pulmonary fibrosis. Respiratory Care 2018;63(8):994-1001.

2017

Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, Geissler K, Hassan AA, Johannson KA, Kairalla R, Kolb M, Kondoh Y, Quadrelli S, Swigris J, Udwadia Z, Wells A, Wijsenbeek M. Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine. 2017 Dec;5(12):968-980. doi: 10.1016/S2213-2600(17)30383-1. 

Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, Hopkins PMA, Corte TJ, Allan H and Glaspole IN. The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation AustraliaRespirology (2017) 22, 1459-1472. doi:10.1111/rep.13163.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. European Respiratory Journal 2017 Aug 31;50(2):1700936. doi: 10.1183/13993003.00936-2017.

Jee AS, Jo HE, Corte TJ. Hypersensitivity pneumonitis: A protean and challenging disease. Respirology. 2017 Nov;22(8):1489-1490. doi: 10.1111/resp.13158. 

 Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh H, Wilsher M, De Boer S, Moddley Y, Grainge C, Whitford H, Chapman S, Reynolds PN, Glaspole I, Beatson D, Jones L, Hopkins P and Corte TJ. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology (2017) 22, 1436-1458. doi:10.1111/resp.13146.

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, Jones LJ, Hopkins P, Allan HM, Glaspole I and Corte TJ. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and the Lung Foundation Australia position statement summaryMedical Journal of Australia 2017; 207(11):1 doi:10.5694/mja17.00799.

Glaspole I.G, Watson A.L, Allan H, Chapman S, Cooper W.A, Corte T.J, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y,  Reynolds P.N, Ryerson C.J, Walters E.H,  Zappala CJ and Holland A.E. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal (2017) 50: 1700168. http://erj.ersjournals.com/content/50/2/1700168.long

Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 2017 Nov;22(8):1592-1597. doi: 10.1111/resp.13084. 

Jee AS, Adelstein S, Bleasel J, Keir GJ, Nguyen M, Sahhar J, Youssef P, Corte TJ. Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). Journal of Clinical Medicine. 2017 May 4;6(5):51. doi: 10.3390/jcm6050051.

Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR. A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine 2017. Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP.

Jo HE, Corte TJ. Nintedanib for idiopathic pulmonary fibrosis in the Japanese population. Respirology. 2017 May;22(4):630-631. doi: 10.1111/resp.13033. 

Glaspole I.N,  Chapman S.A.,  Cooper W.A.,  Ellis S.J.,  Goh N.S., Hopkins P.M, Macansh S., Mahar A., Moodley Y.P., Reynolds P.N., Walters E.H.,  Zappala C.J.  and Corte T.J. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology (2017) doi: 10.1111/resp.12989 

Jo H.E, Glaspole I., Grainge C., Goh N., Hopkins P.M.A, Moodley Y., Reynolds P.N.,  Chapman, S.E. Walters H.E, Zappala C., Allan A., Keir G.J., Hayen A., Cooper W.A., Mahar A.M, Ellis S., Macansh S., and Tamera J. Corte. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal (2017) 49 1601592. http://erj.ersjournals.com/content/49/2/1601592

Khor YH, Goh NS, McDonald CF, Holland AE. Oxygen therapy for interstitial lung disease: Physicians’ perceptions and experiences. Annals of the American Thoracic Society. 2017;14(12):1772-1778.